ACM
CLDX icon

AlphaCrest Capital Management’s Celldex Therapeutics CLDX Stock Holding History

AlphaCrest Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-17,272
Closed -$667K – 1268
2021
Q4 		$667K Buy
+17,272
New +$753K 0.02% 977

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

AlphaCrest Capital Management's CLDX Position: Q1 2022 in Review

AlphaCrest Capital Management sold out of Celldex Therapeutics (CLDX) in Q1 2022, closing a stake of 17,272 shares — an estimated $667K sold.

AlphaCrest Capital Management first reported a position in CLDX in Q4 2021 and held it in 1 quarter. The position peaked at $667K in Q4 2021. 168 funds tracked by Wall St. Rank hold CLDX as of Q1 2022.

  • AlphaCrest Capital Management reported no remaining Celldex Therapeutics position as of Q1 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 17,272 Celldex Therapeutics shares in Q1 2022, an estimated $667K.
  • AlphaCrest Capital Management first reported a position in Celldex Therapeutics in Q4 2021 and held it in 1 quarter.
  • AlphaCrest Capital Management's Celldex Therapeutics position peaked at $667K in Q4 2021.
  • 168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2022.

Based on AlphaCrest Capital Management's 13F filing for Q1 2022, filed 12 May 2022.